| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | HG-5-113-01 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.6 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.6 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.016 | 0.6 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.025 | 0.6 |
| mRNA | purmorphamine | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | NU-7441 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Nilotinib | FIMM | pan-cancer | AAC | -0.095 | 0.7 |